Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Thomas Samuel specializes in all aspects of breast cancer care including breast cancer risk assessment, breast cancer chemoprevention, adjuvant chemotherapy and endocrine therapy for breast cancer, and advanced breast cancer care including palliation. Prior to joining the Cleveland Clinic Florida, Dr. Samuel was Associate Professor of Medicine at the Georgia Regents University-Medical College of Georgia Cancer Center working as the Director of the GRU Multidisciplinary Breast Cancer Program which he founded it in 2006. Dr. Samuel was previously Assistant Professor of Medicine at Fox Chase Cancer Center with a joint appointment at the Temple University School of Medicine in Philadelphia,Pennsylvania. At Fox Chase, Dr.Samuel worked with the nationally renowned Fox Chase Pain Management and Palliative Care Center,where he specialized in cancer-related pain issues and hospice care.
He is currently a member of the multidisciplinary team in breast oncology at Cleveland Clinic Florida as well as active in developing and implementing all phases of clinical and translational research. Dr.Samuel completed his undergraduate training at Swarthmore College and obtained his medical degree from the State University of New York (SUNY) at Stony Brook. He finished a residency in internal medicine at Vanderbilt University Medical Center in Nashville, followed by a specialty fellowship in hematology/oncology at Fox Chase Cancer Center and Temple University School of Medicine. Board certified in internal medicine and medical oncology, his particular interests are in breast cancer treatment with a focus on early development of novel therapeutics, supportive oncology, and palliative care. As a son of a breast cancer survivor, he finds it his unique privilege to take care of patients afflicted with breast cancer at all stages.
Breast Cancer, Palliative Care, Medical Education, Clinical Research
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/1/2016, Dr. Samuel has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.